Clinical Trials

12 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04919369 2026-02-13

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04197934 2026-02-12

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

56 enrolled

CNSThoracic

Astrocytoma, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Lung Neoplasms

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

DermatologicGastrointestinalGenitourinaryThoracic

72 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

NCT03611738 2026-02-09

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04884282 2026-02-06

COMBI-TED

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07389642 2026-02-05

OligoLung

46 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03808662 2026-02-04

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

107 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04073745 2026-02-04

Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer

50 enrolled

Margins of Excision, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04223596 2026-02-04

CUBIK

33 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05616624 2026-02-04

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

31 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05415358 2026-02-03

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

23 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

DermatologicGenitourinaryHead & NeckThoracic

18 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT05340309 2026-01-29

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

5 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

11 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT03824327 2026-01-28

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

19 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04432142 2026-01-27

IPON-1

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05206812 2026-01-27

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05786430 2026-01-27

LUCAS

87 enrolled

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05560776 2026-01-26

OPTIMAL

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplastic Cells, Circulating

NCT05553834 2026-01-23

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04748419 2026-01-22

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

6 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04166487 2026-01-21

Plasma-Adapted First-Line Pembro In NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04743505 2026-01-20

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled